Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Giornale Italiano di Dermatologia e Venereologia 2009 April;144(2) > Giornale Italiano di Dermatologia e Venereologia 2009 April;144(2):103-17

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA

A Journal on Dermatology and Sexually Transmitted Diseases


Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,014


eTOC

 

  WHAT’S NEW IN 2009


Giornale Italiano di Dermatologia e Venereologia 2009 April;144(2):103-17

language: English

What's new in the management of psoriasis?

Kinney M. A. 1, Feldman S. R. 1,2,3

1 Department of Dermatology Center for Dermatology Research Wake Forest University School of Medicine Winston-Salem, NC, USA
2 Department of Pathology Wake Forest University School of Medicine Winston-Salem, NC, USA
3 Public Health Sciences Wake Forest University School of Medicine Winston-Salem, NC, USA


PDF  


Psoriasis treatment is evolving through better understanding of patients with psoriasis and the pathogenesis of the disease itself. Current treatment plans for psoriasis consist of topical medications for mild-moderate or localized psoriasis and more systemic agents for more generalized and moderate-severe psoriasis. New methods of treatment involve not only prescriptions, but patient education and support through organizations such as the National Psoriasis Foundation. The effectiveness of topical treatments have been improved by a better understanding of increasing patients’ adherence to medications and new treatments—new vehicles and combination treatments—that enhance patients’ adherence behaviors. Phototherapy, with or without an oral retinoid, remains a key component of psoriasis treatment. More convenient and specific monitoring of methotrexate and biologic medications provide these standards of care in psoriasis better and safer patient outcomes. New anti-IL-12/23 therapies offer another more specific option in the management of chronic plaque psoriasis. Dermatologists should recognize and educate patients about the recently recognized association between psoriasis and vascular disease. Psoriasis management can include counseling patients to obtain appropriate screening for cardiovascular risk.

top of page

Publication History

Cite this article as

Corresponding author e-mail